Fractyl Health Inc (GUTS)

Apr 1, 2025, 7:00 AM EDT - 5 days ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 4 weeks ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 4 weeks ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 2 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 4 months ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 4 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 4 months ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 5 months ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 5 months ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 5 months ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 5 months ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 5 months ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 6 months ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 7 months ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 8 months ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 8 months ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 7, 2024, 7:00 AM EDT - 8 months ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

Jul 30, 2024, 7:00 AM EDT - 8 months ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Jun 25, 2024, 7:00 AM EDT - 10 months ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Jun 24, 2024, 6:00 AM EDT - 10 months ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Jun 23, 2024, 1:30 PM EDT - 10 months ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's

May 20, 2024, 6:00 AM EDT - 11 months ago

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

May 13, 2024, 10:37 PM EDT - 11 months ago

Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:00 PM EDT - 11 months ago

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 6:00 AM EDT - 11 months ago

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

May 8, 2024, 6:00 AM EDT - 11 months ago

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

May 7, 2024, 6:00 AM EDT - 11 months ago

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Apr 30, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Mar 19, 2024, 8:08 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

IVP OM PACB

Mar 12, 2024, 2:06 PM EDT - 1 year ago

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Mar 12, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Feb 20, 2024, 8:38 AM EST - 1 year ago

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Feb 4, 2024, 6:16 AM EST - 1 year ago

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

AS AHR AMDI ANRO FBLG FLUT KYTX

Feb 2, 2024, 1:44 PM EST - 1 year ago

Fractyl Health valued at $654.6 mln in tepid debut

Feb 1, 2024, 9:39 PM EST - 1 year ago

Fractyl Health prices US IPO below range to raise $110 mln

Feb 1, 2024, 8:08 PM EST - 1 year ago

Fractyl Health Announces Pricing of Initial Public Offering

Dec 17, 2023, 4:47 AM EST - 1 year ago

Fractyl Health Aims For $100 Million IPO Raise

Dec 16, 2023, 3:35 AM EST - 1 year ago

U.S. IPO Weekly Recap: Chinese Issuer ZKH Slips Through The U.S. IPO Window

INHD ZKH EIL